Nanoparticles for multimodal in vivo imaging in nanomedicine

Key, Jaehong; Leary, James F.

doi:10.2147/ijn.s53717

Cited by 117 publications

(57 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These materials have demonstrated numerous advantages, such as high target specificity, extended drug release and biodegradability of the carrying materials. The advantages of these drug carriers have made them promising in applications including early diagnosis [16], target treatment [17], real-time imaging in vivo [18] and the development of novel technology. Compared to conventional drugs, nano drugs have multiple advantages: (1) better membrane permeability and reduced drug resistance, (2) increased drug accumulation at the tumor site through enhanced permeability and retention (EPR) effect, (3) highly specific effects on specific tissues or cells through functional ligand binding, and (4) ability to overcome the cell membranes and lysosomal barrier and reduced regional degradation [19].…”

Section: Discussionmentioning

confidence: 99%

Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM–PLGA microspheres for bone cancer treatment

Rong

Yang

Cai

et al. 2016

J Mater Sci: Mater Med

View full text Add to dashboard Cite

To develop adriamycin (ADM)-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles in a porous nano-hydroxyapatite/collagen scaffold (ADM-PLGA-NHAC). To provide novel strategies for future treatment of osteosarcoma, the properties of the scaffold, including its in vitro extended-release properties, the inhibition effects of ADM-PLGA-NHAC on the osteosarcoma MG63 cells, and its bone repair capacity, were investigated in vivo and in vitro. The PLGA copolymer was utilized as a drug carrier to deliver ADM-PLGA nanoparticles (ADM-PLGA-NP). Porous nano-hydroxyapatite and collagen were used to materials to produce the porous nano-hydroxyapatite/collagen scaffold (NHAC), into which the ADM-PLGA-NP was loaded. The performance of the drug-carrying scaffold was assessed using multiple techniques, including scanning electron microscopy and in vitro extended release. The antineoplastic activities of scaffold extracts on the human osteosarcoma MG63 cell line were evaluated in vitro using the cell counting kit-8 (CCK8) method and live-dead cell staining. The bone repair ability of the scaffold was assessed based on the establishment of a femoral condyle defect model in rabbits. ADM-PLGA-NHAC and NHAC were implanted into the rat muscle bag for immune response experiments. A tumor-bearing nude mice model was created, and the TUNEL and HE staining results were observed under optical microscopy to evaluate the antineoplastic activity and toxic side effects of the scaffold. The composite scaffold demonstrated extraordinary extended-release properties, and its extracts also exhibited significant inhibition of the growth of osteosarcoma MG63 cells. In the bone repair experiment, no significant difference was observed between ADM-PLGA-NHAC and NHAC by itself. In the immune response experiments, ADM-PLGA-NHAC exhibited remarkable biocompatibility. The in vivo antitumor experiment revealed that the implantation of ADM-PLGA-NHAC in the tumor resulted in a improved antineoplastic effect and fewer adverse side effects than direct intraperitoneal injection of ADM. The ADM-PLGA-NHAC developed in this study exhibited excellent extended-release drug properties, bone repairing and antineoplastic efficacy, which make it a promising osteoconductivity material with the capability to inhibit osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM–PLGA microspheres for bone cancer treatment

Rong

Yang

Cai

et al. 2016

J Mater Sci: Mater Med

View full text Add to dashboard Cite

show abstract

“…Thus, near-infrared fluorescent (NIRF) imaging has been primarily applied in small-animal imaging, for which several probes have been developed. These probes include synthetic fluorophores, semiconductor fluorescent crystals, and probes based on lanthanide rare-earth ions [215]. Quantum dots have also been investigated in pre-clinical applications; however, their clinical utility has been challenging due to toxicity concerns.…”

Section: Targeted Nanoparticle Imaging Agentsmentioning

confidence: 99%

Targeted nanotechnology for cancer imaging

Toy

Bauer

Hoimes

et al. 2014

Advanced Drug Delivery Reviews

167

100

View full text Add to dashboard Cite

Targeted nanoparticle imaging agents provide many benefits and new opportunities to facilitate accurate diagnosis of cancer and significantly impact patient outcome. Due to the highly engineerable nature of nanotechnology, targeted nanoparticles exhibit significant advantages including increased contrast sensitivity, binding avidity and targeting specificity. Considering the various nanoparticle designs and their adjustable ability to target a specific site and generate detectable signals, nanoparticles can be optimally designed in terms of biophysical interactions (i.e., intravascular and interstitial transport) and biochemical interactions (i.e., targeting avidity towards cancer-related biomarkers) for site-specific detection of very distinct microenvironments. This review seeks to illustrate that the design of a nanoparticle dictates its in vivo journey and targeting of hard-to-reach cancer sites, facilitating early and accurate diagnosis and interrogation of the most aggressive forms of cancer. We will report various targeted nanoparticles for cancer imaging using X-ray computed tomography, ultrasound, magnetic resonance imaging, nuclear imaging and optical imaging. Finally, to realize the full potential of targeted nanotechnology for cancer imaging, we will describe the challenges and opportunities for the clinical translation and widespread adaptation of targeted nanoparticles imaging agents.

show abstract

“…VEGF) for direct tumor targeting are improving MRI resolution and tumor identification [47,48,49]. Traditional contrast agents formulated onto nanocarriers better facilitate intra-tumoral uptake and minimize nephrotoxicity, as demonstrated by gadolinum nanoparticles for MRI and liposomal iodinated contrast agents for computed tomography [50,51]. These improvements have the potential to greatly improve lung cancer diagnosis and staging, particularly given the suboptimal diagnostic accuracy (79%) and sensitivity (64%) of conventional CT-PET scans as well as the risk for nephrotoxity associated with each intravenous dose of traditional iodinated contrast [52].…”

Section: Potential Clinical Application Of Nanotechnology In Thoracicmentioning

confidence: 99%

From Diagnosis to Treatment

Digesu

Hofferberth

Grinstaff

et al. 2016

Thoracic Surgery Clinics

View full text Add to dashboard Cite

Synopsis Nanotechnology is an emerging field of medicine with significant potential to become a powerful adjunct to cancer therapy, and in particular, thoracic surgery. Using the unique properties of several different nanometer-sized platforms, therapy can be delivered to tumors in a more targeted fashion, with less of the systemic toxicity associated with traditional chemotherapeutics. In addition to the packaged delivery of chemotherapeutic drugs, nanoparticles show potential to aid in the diagnosis, pre-operative characterization, and intraoperative localization of thoracic tumors and their lymphatics. With increasing interest in their clinical application, there is a rapid expansion of in vitro and in vivo studies being conducted that provide a better understanding of potential toxicities and hopes of broader clinical translation. Focused research into nanotechnology’s ability to deliver both diagnostics and therapeutics has led to the development of a field known as nanotheranostics which promises to improve the treatment of thoracic malignancies through enhanced tumor targeting, controlled drug delivery, and therapeutic monitoring. This article reviews the various types of nanoplatforms, their unique properties, and the potential for clinical application in thoracic surgery.

show abstract

Nanoparticles for multimodal in vivo imaging in nanomedicine

Cited by 117 publications

References 90 publications

Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM–PLGA microspheres for bone cancer treatment

Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM–PLGA microspheres for bone cancer treatment

Targeted nanotechnology for cancer imaging

From Diagnosis to Treatment

Contact Info

Product

Resources

About